<DOC>
	<DOCNO>NCT00755742</DOCNO>
	<brief_summary>Chronic hepatitis C ( CHC ) infection affect approximately 1 100 Canadians . Untreated , CHC significant long-term consequence include cirrhosis , liver cancer liver failure . CHC intrinsically link obesity insulin resistance ( IR ) `` pre-diabetes '' , co-existence worsens overall health outcome . We demonstrate obesity ( BMI ≥30kg/m2 ) twice common amongst patient CHC ( 28.8 % ) compare general Canadian population . Obesity superimpose CHC reduces success antiviral treatment promotes liver scar ( hepatic fibrosis ) , fatty liver ( steatosis ) increase risk liver cancer . Both CHC obesity contribute IR put patient risk type 2 diabetes . IR , like obesity CHC , reduce antiviral success rate . We show diabetic higher risk develop liver cancer compare non-diabetics . It therefore timely address lifestyle modification delay onset diabetes . We examine impact multidisciplinary lifestyle program insulin resistance 52 obese `` pre-diabetic '' patient current past CHC . The 24 week program comprises individualize nutritional exercise plan support behavior modification counseling . Through gain well understanding link obesity , insulin resistance hepatitis C infection hope delay onset diabetes reduce likelihood untoward effect liver .</brief_summary>
	<brief_title>Lifestyle Intervention Targetting Obesity Insulin Resistance Chronic Hepatitis C</brief_title>
	<detailed_description>The hepatitis C virus ( HCV ) chronically infect estimate 240,000 Canada 170 million worldwide . Untreated , CHC associate significant long-term clinical consequence include cirrhosis , liver failure hepatocellular cancer ( HCC ) , common indication liver transplantation North America . CHC associate metabolic manifestation independent degree hepatic fibrosis include insulin resistance ( IR ) type 2 diabetes ( T2DM ) , significantly high prevalence CHC compare general population . Patients CHC T2DM increase risk HCC addition morbidity systemic complication . Our previous work demonstrate prevalence obesity ( BMI ≥30kg/m2 ) amongst patient CHC 28.8 % , twice prevalence Canadian population , presence obesity independently associate viremia ( positive HCV-RNA ) . Obesity promote hepatic fibrosis progression independently associate IR non-cirrhotic CHC ; prevalence IR increase high BMI CHC . Insulin resistance reverse viral clearance achieve ; however loss IR less likely occur obese even clear virus . Obesity IR associate non-response antiviral therapy . Whilst IR improve use metformin patient CHC , ineffective increase rate response antiviral treatment . The aim study : 1 . To evaluate effect three-pronged lifestyle intervention comprise diet , exercise behavior modification insulin resistance obese patient current cure chronic hepatitis C. 2 . To formulate specific recommendation lifestyle change improve insulin resistance lose weight , thereby reduce risk diabetes metabolic complication , potentially enhance response antiviral therapy obese patient CHC . 3 . To examine impact intervention IR , insulin sensitivity serum adipokine level purpose investigate mechanism insulin resistance obesity without viremia due chronic hepatitis C infection . We utilize multidisciplinary approach collaborate discipline gastroenterology , nutrition , endocrinology , exercise physiology psychiatry . This prospective study include 13 non-cirrhotic 13 cirrhotic , insulin resistant ( HOMA-IR ≥2.1 ) obese patient ( non-Genotype 3 , latter mark fatty liver absence obesity ) ; well 13 non-cirrhotic 13 cirrhotic , insulin resistant obese patient successfully treat CHC ( ie non-viremic ) act control . Assessments measure IR obesity ( include oral glucose tolerance test calculate insulin sensitivity index ( ISI ) , serum adipokines , free fatty acid , anthropometry body composition abdominal DEXA ) make . The HOMA-IR ( measure hepatic IR ) primary outcome experimental maneuver , take place 24 week . It comprise 3 component : 1 . Diet : participant advise individually tailor diet low glycemic food , low total fat ( rich omega-3 fatty acid ) high fiber aim weight loss improvement insulin resistance . 2 . Exercise : physical activity measure use personal pedometer , participant give step target 10000 step per day , increment 3000 step per day baseline activity ( whichever great ) . 3 . Behavior Modification : change diet physical activity facilitate 12-week face-to face program follow 12-week telephone program base principal motivational interview behavior theory . The intercurrence obesity IR subject chronically infect hepatitis C exacerbate poor current future health status . As pathophysiology IR patient CHC may differ obese longer infect , quantify benefit lifestyle intervention two patient group gauge fall HOMA-IR score improvement ISI . Our long-term goal improve outcome antiviral therapy reduce burden CHC , obesity type 2 diabetes related morbidity . This hope achieve gain well understanding mechanism involve development IR obese without current CHC .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>obese ( BMI &gt; /= 30 ) insulin resistant ( HOMAIR &gt; /= 2.1 ) Genotype 3 patient Women ongoing pregnancy breastfeed Patients underlie liver disease ( viral , alcoholic , druginduced , autoimmune , metabolic , genetic ) . Patients currently antiviral therapy , cease therapy within 6 month recruitment study . Patients cause insulin resistance e.g. , excess counterregulatory hormone : glucocorticoid , catecholamine , growth hormone , polycystic ovary syndrome ) . Patients steroids drug affect insulin resistance , unable stop 3 day prior IR test . Patients overt diabetes ( base result fast plasma glucose ) exclude participation focus insulin resistance absence diabetes . Conditions preclude sudden increase physical activity : History evidence chronic pulmonary disease associate functional limitation . History severe cardiac disease ( e.g. , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) . Unable 10000 steps/day eg physical disability , morbid obesity . Evidence ongoing substance use ( include alcohol consumption &gt; 20g/day men &gt; 10g/day woman ) within one year study recruitment . Poor vein ( inadequate venous access ) Inability unwillingness provide inform consent abide study requirement eg severe psychiatric illness , live remotely , time commitment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>obesity</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>adipokine</keyword>
	<keyword>TNF</keyword>
	<keyword>leptin</keyword>
	<keyword>adiponectin</keyword>
	<keyword>fatigue</keyword>
	<keyword>mood</keyword>
	<keyword>depression</keyword>
	<keyword>exercise</keyword>
	<keyword>diet</keyword>
	<keyword>counsel</keyword>
	<keyword>behavior modification</keyword>
</DOC>